A B S T R A C T The effect of large doses of glucocorticoids on thyrotropin (TSH) secretion in normal and hypothyroid humans has been studied. Plasma TSH concentrations were measured before, during, and after treatment with dexamethasone given orally for 24-48 hr. In 17 patients with primary hypothyroidism, plasma TSH levels fell significantly during treatment to a mean of 54% of control (range 23-96%). Within 48 hr after the withdrawal of dexamethasone, TSH concentrations transiently increased above pretreatment values. The mean increase was to 156% of control (range . Similar changes, but of smaller magnitude, were observed in 15 normal subjects. Administration of single oral doses of dexamethasone and oral or intravenous doses of cortisol were followed by reduction of plasma TSH levels to 18-47% of control within 8-12 hr in eight hypothyroid patients. This fall also was followed by significant TSH rises above control values before they returned to the pretreatment levels. Mineralocorticoid administration was not followed by any changes in plasma TSH concentrations in three subjects.
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TSH responses to steroid were also studied in rats. In hypothyroid rats given dexamethasone intravenously, plasma TSH fell to 63% of control in 30-90 min and then returned to normal or above in 3-4 hr. Dexamethasone also reduced plasma TSH concentrations in normal rats but no rebound was observed in these animals. Dexamethasone did not block the increase in plasma TSH produced by thyrotropin releasing factor (TRF) administration in vivo. Neither basal nor TRF-mediated TSH release from hemipituitaries in vitro was reduced by dexamethasone or corticosterone. These studies indi-INTRODUCTION Considerable evidence indicates that both natural and synthetic glucocorticoid hormones inhibit various paramReceived for publication 19 May 1969 and in revised form 7 July 1969. eters of thyroid function in both man and laboratory animals. Thyroidal iodide clearance rates, thyroid 24 and 48 hr iodide uptake values, thyroid secretion rates, plasma protein-bound iodide (PBI) concentrations, and various other less direct indices of thyroid function have all been shown to fall after administration of these agents in large doses (1) (2) (3) (4) . The magnitude of these changes is frequently considerable and, in some patients, iodide uptake or clearance measurements and plasma thyroid hormone concentrations fall to values ordinarily found only in hypothyroid patients. Some of these effects have been reported to occur within 1 day after glucocorticoid administration is initiated (5) and they generally persist as long as steroids are administered. However, they are entirely reversible. Reductions in PBI do not occur when glucocorticoids are given to hypothyroid patients receiving thyroid replacement therapy (6) . Changes in peripheral thyroxine metabolism and in the pattern of thyroxine binding to plasma proteins during glucocorticoid treatment have also been described (6) (7) (8) .
The mechanism of the thyroid suppression produced by glucocorticoids is unknown though most of the published data are consistent with the hypothesis that glucocorticoids impair the secretion of thyrotropin (TSH) from the anterior pituitary gland. This report provides direct evidence that TSH secretion is altered during and after glucocorticoid administration and that the effect of these agents is exerted at a suprahypophyseal level, rather than on the pituitary gland itself. METHODS Studies in human subjects. All studies were carried out in hospitalized subjects. The patients' diagnoses were established by appropriate clinical and laboratory observations including measurement of plasma PBI and thyroxine (9) and thyroidal radioiodide uptake at 6 and 24 hr. All the clinically hypothyroid patients studied had elevated plasma TSH concentrations, thus confirming the diagnosis of primary hypothyroidism. Glucocorticoids were given according to three regimens. The first consisted of oral administration of 2 or 8 mg dexamethasone in divided doses for 1-2 days. The second involved single oral doses of dexamethasone or cortisol. Lastly, two patients received cortisol intravenously. (13) . This system can detect as little as 5 ,uU TSH/ml plasma and its reproducibility is similar to that of the human TSH assay.
RESULTS

Studies in hypothyroid patients
During the control period, plasma TSH concentrations were quite constant in each of the 17 patients.
The average difference of the pretreatment values from their mean was +-10.7% and, in any individual study, no result differed by more than ±27% of the mean for that patient. The data from all the patients who received multiple doses of dexamethasone are shown in Table I and two individual responses are shown in Fig. 1 values while steroid was still being given. Considering the group as a whole (Fig. 2) , the lowest plasma TSH concentration found ranged from 23 to 96% of control (mean 54%). This difference is statistically significant (P < 0.01). TSH reductions to 50% of control or less occurred in nine patients. Since neither the fall in TSH during treatment nor the rise after it (see below) appeared to depend on the dose or duration of dexamethasone treatment, all results have been considered together in this analysis. In 14 of the studies, after steroid administration, plasma TSH concentrations rose transiently above control levels. A striking example of this is shown in Fig.  1 A, whereas its absence is apparent in the data shown in Fig 1 B . The highest TSH value was observed within 48 hr after steroids were discontinued and usually it occurred within 36 hr after the last dose. Rises to values greater than 150% of control were found in six patients.
The peak plasma TSH for the individual patients ranged from 106 to 294% of control, the mean being 156% of it (Fig. 2) . This value is also significantly different from control (P < 0.01). It is apparent from inspection of Table I and Fig. 2 single oral doses of dexamethasone or cortisol given orally or intravenously (Table II) . As expected from the results presented in Table I , in all studies a fall in plasma TSH occurred. This fall was also unrelated to the dose, type, or route of administration of steroid employed. Fig. 3 shows the results obtained with two different doses of cortisol in one patient. The TSH reduction was often apparent within 2-4 hr and was usually -maximal 8 or 12 hr after steroid administration. The mean maximal TSH fall in this entire group was to 35% of control values and ranged from 18 to 47% (Fig. 4) and was highly statistically significant (P < 0.005). Thereafter, plasma TSH concentrations returned to control values (three patients) or above (five patients), the highest observed values in this group of studies ranging from 76 to 182% of control (mean 134%). This peak occurred 24 or 36 hr after steroid administration. The lack of an appreciable "rebound" in several patients may have been due to insufficient study duration. Thus, the responses to single dose steroid administration were similar to those observed in the more numerous multple dose studies. Three studies were carried out after mineralcorticoid (9 a-fluorohydrocortisone) administration (Table II) . No changes in plasma TSH were observed.
Studies in normal subjects
Dexamethasone was also given orally in multiple doses to 15 normal subjects (Table III) . Plasma TSH concentrations were initially detectable in each of these subjects and quite constant in each during the pretreatment sampling period. The average difference from the mean of the pretreatment values was ±10.1% and no value differed by more than ±25% of the mean in any subject. The pattern of response was similar to that observed in the hypothyroid patients, though the magni- 
Studies with metyrapone
The effect of metyrapone on TSH secretion was examined in 6 normal and 15 hypothyroid subjects. In the normal subjects, plasma TSH concentrations did not vary by more than ±20% of control at any time during or after administration of this agent. Similar findings were observed in nine of the hypothyroid subjects. However, in six of the latter group, rises in plasma TSH concentrations to values greater than 140% of control occurred during the period of administration. All subjects had normal urinary 17-hydroxycorticosteroid responses to the metyrapone (14) .
Studies in rats
In vivo studies. The administration of 100 ig dexamethasone intravenously to anesthetized normal rats was followed by a significant fall in plasma TSH (Fig. 6) . No change occurred in animals not given steroid. The TSH reduction was apparent within 30 min and was maximal 1 hr after steroid administration, the mean TSH value being 48% of control at that time. Postinjection values in the dexamethasone-treated animals differed significantly (P < 0.01) from those in the salinetreated animals at all times except at 2 and 4 hr. (Fig. 7) . It has previously been shown that plasma TSH levels remained quite constant when anesthetized hypothyroid rats were given saline intravenously (13) . In other animals the ability of dexamethasone to block the action of TRF in vivo was examined. After anesthesia and catheter implantation, 100 lg dexamethasone and 25 Ag TRF were given intravenously. Controls received only TRF. The results are shown in Fig. 8 . In both groups of animals, plasma TSH concentrations increased significantly (P<0.01) promptly after TRF injection. Neither the magnitude nor the duration of the TRF-induced plasma TSH increase was modified by the administration of dexamethasone. Insufficient TRF was available to test the possibility that the effect of larger doses might be blunted by glucocorticoids.
In vitro studies. Additional studies to examine the effect of steroids on TRF-mediated TSH secretion were carried out in vitro. The results are shown in Table IV Hemipituitaries were also incubated with dexamethasone starting immediately after their removal and hourly changes in medium were made for 4 hr. The usual pattern of fall of medium TSH concentrations to stable levels of approximately 10% of the 1st hour concentration by the 3rd and 4th hours was observed in media from hemipituitaries incubated both with and without steroid. Thus, basal TSH release in vitro was also unaffected by steroid.
DISCUSSION
The studies herein described clearly demonstrate that glucocorticoid administration results in reduction in plasma TSH concentrations in both hypothyroid and normal human subjects. Thus, these data provide direct support for the hypothesis of Ingbar and Freinkel concerning glucocorticoid inhibition of thyroid function (3) . The TSH suppressive effect of glucocorticoids occurs within hours after their administration and the tendency for plasma TSH concentrations to return toward the pretreatment level during steroid treatment in some subjects suggests the potentiality for escape from this process. The responses to prolonged steroid administration have not been examined in detail, but in one hypothyroid patient given 40 mg prednisone daily for 2 wk the plasma TSH fell from 23 to 3.5 mpg/ml. The fall in TSH in normal subjects was of lesser magnitude and the percentage changes smaller than those observed in the hypothyroid patients. However, control plasma TSH concentrations were often so near the sensitivity threshold of the assay in the normal subjects that greater falls in plasma TSH that could not be appreciated may have occurred. The doses required to produce these changes were not large and, at least within the range used in this study, larger doses of steroid did not result in greater TSH changes. Moreover, similar patterns of change followed administration of both single and mul- (15) . Alternatively, the action of glucocorticoids might be to accelerate the degradation of TSH by peripheral tissue or to increase the TSH distribution space. These possibilities have not been investigated but seem unlikely. Accelerated degradation or altered distribution of TSH might explain the fall in plasma TSH concentrations observed; it is difficult to see how such a mechanism could result in the post-treatment rebound. Glucocorticoids have been shown to reduce the binding capacity of plasma thyroxine binding globulin (TBG) and increase that of thyroxine binding prealbumin (TBPA) (8) . Since no changes in net thyroxine binding were reported in that study and the changes described took at least a week to develop, glucocorticoid effects on thyroxine transport cannot account for the TSH changes reported herein.
TSH rebound was observed in a high proportion of both hypothyroid and normal human subjects and hypothyroid rats. During glucocorticoid treatment when TRF secretion is presumably impaired, it could accumulate intracellularly in the appropriate hypothalamic centers. Subsequently, this accumulated TRF might be rapidly released and therefore briefly stimulate TSH secretion through its known pituitary action. Whatever the mechanism of the TSH rebound, it represents the first demonstration of increased TSH secretion in the adult not resulting from either reduced circulating thyroid hormone concentrations or TRF administration (16) . It also suggests that alterations in TSH secretion are not determined entirely by changing plasma thyroid hormone levels interacting with unvarying TRF concentrations at the level of the pituitary thyrotroph, but that alterations in TRF secretion can also participate in regulating TSH secretion. The secretion of several anterior pituitary hormones in man has been shown previously to be altered by glucocorticoids. That these agents regulate ACTH secretion is well known and effects on MISH secretion have also been described (17) . Impairment of the increase in plasma growth hormone (GH) which follows insulin-induced hypoglycemia during glucocorticoid administration has been reported during some but not all experimental conditions (18) (19) (20) (21) , whereas the rise in plasma GH provoked by arginine infusion is not impaired by short-term steroid treatment (20) . While the glucocorticoid doses used were supraphysiologic, it has herein been shown that TSH should be added to the number of anterior pituitary hormones whose secretion is reduced by these agents and it is the first for which a rise above control values has been observed after treatment.
